Pegylation: engineering improved pharmaceuticals for enhanced therapy
- 1 January 2002
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 28, 13-16
- https://doi.org/10.1016/s0305-7372(02)80004-4
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis CJournal of Controlled Release, 2001
- Efficacy and Safety of Pegylated (40–Kd) Interferon α–2A Compared With Interferon α–2A in Noncirrhotic Patients With Chronic Hepatitis CHepatology, 2001
- Peptide and protein PEGylation: a review of problems and solutionsPublished by Elsevier ,2001
- Randomized, Dose-Escalation Study of SD/01 Compared With Daily Filgrastim in Patients Receiving ChemotherapyJournal of Clinical Oncology, 2000
- Controlled-Release, Pegylation, Liposomal Formulations: New Mechanisms in the Delivery of Injectable DrugsAnnals of Pharmacotherapy, 2000
- A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humansExperimental Hematology, 1999
- Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor muteinExperimental Hematology, 1999
- Polyethylene glycol-conjugated pharmaceutical proteinsPharmaceutical Science & Technology Today, 1998
- Polyethylenglykol-umhülltes (pegyliertes) liposomales DoxorubicinDrugs, 1997
- Characterization and Stability of N-terminally PEGylated rhG-CSFPharmaceutical Research, 1996